Albany College of Pharmacy and Health Sciences, Albany, New York, USA.
Genesis Research Inc, Hoboken, New Jersey, USA.
Pharmacotherapy. 2020 Sep;40(9):889-901. doi: 10.1002/phar.2446. Epub 2020 Aug 18.
Serious bloodstream infections (BSIs) are often caused by Gram-negative (GN) bacteria in hospitalized patients. Treatment of these infections has been further complicated by the continued rise and spread of drug-resistant pathogens, including carbapenem resistant (CR) strains of Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa.
This retrospective cohort analysis used real-world data from a large United States hospital-based database to examine the association between key clinical outcomes and different lengths of time to appropriate treatment between October 2010 and September 2015.
Of 40,549 patients with GN-BSIs who were identified, 1117 (2.8%) had a CR GN-BSI. Overall, outcomes of hospitalized adult patients with GN-BSIs incrementally worsened the longer appropriate therapy was delayed. Patients with CR GN-BSIs had a median infection-associated length of stay (LOS) of 8, 9, 10, and 13 days, whereas patients with CS GN-BSIs had a median infection-associated LOS of 6, 7, 8, and 11 days for patients with days to appropriate therapy of 0, 1-2, 3-4, and ≥ 5 days, respectively. Among patients with CR GN-BSIs, the percentage of patients discharged home was 38%, 33%, 35%, and 31%, whereas in patients with CS GN-BSIs, the percentage of patients discharged home was 58%, 53%, 48%, and 43% for patients with days to appropriate therapy of 0, 1-2, 3-4, and ≥ 5 days, respectively.
The findings from this study highlight the clear need to deliver appropriate therapy more expeditiously in patients with CS and CR GN-BSIs.
严重血流感染(BSI)通常由住院患者中的革兰氏阴性(GN)细菌引起。这些感染的治疗因耐药病原体(包括耐碳青霉烯类肠杆菌科、鲍曼不动杆菌和铜绿假单胞菌)的持续上升和传播而变得更加复杂。
本回顾性队列分析使用来自美国大型医院数据库的真实世界数据,研究了 2010 年 10 月至 2015 年 9 月期间不同适当治疗时间与关键临床结局之间的关联。
在确定的 40549 例 GN-BSI 患者中,有 1117 例(2.8%)为耐碳青霉烯类肠杆菌科 GN-BSI。总体而言,GN-BSI 住院成年患者的结局随着适当治疗时间的延迟而逐渐恶化。耐碳青霉烯类 GN-BSI 患者的感染相关住院时间中位数分别为 8、9、10 和 13 天,而碳青霉烯敏感 GN-BSI 患者的感染相关住院时间中位数分别为 6、7、8 和 11 天,分别为适当治疗时间为 0、1-2、3-4 和≥5 天的患者。在耐碳青霉烯类 GN-BSI 患者中,出院回家的患者比例分别为 38%、33%、35%和 31%,而在碳青霉烯敏感 GN-BSI 患者中,出院回家的患者比例分别为 58%、53%、48%和 43%,分别为适当治疗时间为 0、1-2、3-4 和≥5 天的患者。
本研究结果强调了在碳青霉烯敏感和耐碳青霉烯类肠杆菌科 GN-BSI 患者中,更迅速地给予适当治疗的迫切需要。